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Efforts toward a stereocontrolled synthesis of 






 Several furocoumarin compounds that show significant inhibition of 
the main human metabolic enzyme CYP3A4 have been isolated from 
grapefruit juice.  The most potent of these is GF-I-1, an asymmetrical 
homodimer whose stereochemistry remains unknown.  We sought to 
synthesize GF-I-1 and its three stereoisomers in a stereocontrolled fashion to 
unambiguously determine the absolute stereochemistry of natural GF-I-1.  
We were also interested in comparing the biological activities of the four 
synthetic isomers, following work that showed that CYP3A4 is not sensitive 
to the absolute configuration of a simpler grapefruit furocoumarin. 
 We have achieved the synthesis of a key dimeric intermediate in 
racemic form on the route towards GF-I-1.  In doing so, we assessed the 
efficiencies of BiCl3 and CuII(BF4)2, two newly-discovered Lewis acid 
catalysts, for promoting the condensation of precious alcohols and epoxides.  
CuII(BF4)2 appears to be a promising catalyst for these transformations, for 
which well-established synthetic protocols have been notably absent. 
 We also progressed along the stereocontrolled route towards GF-I-1 
and its stereoisomers, with the stereospecific synthesis of all required chiral 
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precursors in greater than 96% enantiomeric excess.  While the total 
synthesis was not completed due to a transformation that could not be 
efficiently accomplished during the allotted time for the project, we have laid 




Introduction and Background 
 
In 1989, a drug interaction between grapefruit (Citrus paradisii) and 
felodipine, a dihydropyridine calcium channel antagonist, was serendipitously 
discovered by Bailey et al.  They were investigating the interaction of 
felodipine and ethanol, using grapefruit juice as the delivery vehicle.1  When 
felodipine was ingested with grapefruit juice, the plasma concentrations of 
the drug were more than five-fold greater than when taken with water.  It 
was known that the bioavailability of felodipine typically averages only 15% 
due to exhaustive first-pass metabolism.2  This, coupled with the observation 
that grapefruit juice has no effect on the elimination of plasma felodipine,3 
suggested that regulation of the first-pass enzyme by compounds in the 
grapefruit juice may be responsible for the observed drug interaction.  A 
search for that first-pass enzyme yielded cytochrome P450 3A4.4 
Cytochrome P450 enzymes are a class of heme-containing proteins that 
generally catalyze the oxidation of their substrates.  Of the many cytochrome 
P450 isoforms present, cytochrome P450 3A4 (CYP3A4) is the most abundant 
in the liver and epithelial tissue of the small intestine.5  It has been 
implicated in metabolizing approximately 50% of the clinical drugs on the 
market as well as a broad range of xenobiotics.6  For example, it is known 
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that CYP3A4 catalyzes the conversion of polycyclic aromatic hydrocarbons 
(PAHs) and heterocyclic amines (HAs) to reactive electrophiles.  These 
metabolites from PAHs, often referred to as diol epoxides, react with DNA, 
and thus exert carcinogenic and mutagenic effects.7 
Once the target metabolic enzyme CYP3A4 was identified, work 
ensued in identifying the compounds present in grapefruit that are 
responsible for altering its biological activity.  A series of furocoumarins and 
furocoumarin dimers were isolated and their structures characterized from 
fractions of organic extracts of grapefruit juice that showed inhibition of 
CYP3A4.8  Of these, the most potent inhibitor was determined to be GF-I-1 
(recently renamed: Paradisin A), a furocoumarin dimer that is a mechanism-
based competitive inhibitor of CYP3A4, with an IC50 on the order of 10 nM.9 
It should be mentioned that neither do the grapefruit furocoumarins 
inhibit CYP3A4 exclusively nor are they the only known inhibitors of 
CYP3A4.  The furocoumarins present in grapefruit have been shown to 
inhibit several other P450 isoforms.9  They recently have also been observed 
to interact with P-glycoprotein, a membrane-localized drug transporter, thus 
inhibiting the cellular efflux of its targets.10  CYP3A4 has long been known to 
be inhibited by Ketoconazole,11 an anti-fungal drug, and recently a new class 
of bisalkaloids from white pepper that also possess moderate CYP3A4 
inhibitory activity has been isolated.12 
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 While the structures of the furocoumarins present in grapefruit have 
been identified, the stereochemical properties of these chiral molecules have 
not been unambiguously elucidated.  Previously, through a total 
stereocontrolled synthesis, our laboratory has unambiguously determined the 
absolute stereochemistry of natural 6,7-dihydroxybergamottin (DHB), 
another CYP3A4 inhibitor from grapefruit that is somewhat less potent but 
more synthetically accessible than GF-I-1 (Figure 1).13  Furthermore, the 
CYP3A4 inhibition activity of the two stereoisomers of DHB were compared 
against each other as well as racemic DHB, revealing that all three activities 
are nearly equivalent.  This suggested that the portion of DHB containing the 





















Figure 1.  Synthetic target. 
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 We now turned our attention towards the more potent GF-I-1 
furocoumarin dimer.  The absolute stereochemistry of this compound has 
been proposed to be (6R, 6'R) through 1H NMR studies of the corresponding 
Mosher esters,14 however this method has been known to give erroneous 
results.15,16  We decided to unambiguously determine the absolute 
stereochemistry of GF-I-1 using a synthetic approach.  We were also 
interested in comparing the inhibition activities of the four GF-I-1 
diastereomers.  In this dissertation, we describe our efforts toward the 




Synthesis of Racemic Model System 
 
 The greatest challenge that we anticipated in the synthesis of GF-I-1 
was the coupling of the two geranyl chains to form the ether-linked dimer.  In 
fact, prior to the very recent work by Barluenga et al.,17 the literature was 
void of any systematic protocol for opening precious epoxides with precious 
alcohols.  Cognizant of this difficulty, we synthesized a racemic model system 
for conducting epoxide-opening trials. 
 Starting with the commercially available geraniol (1), the racemic 
epoxide (3) and diol (4) were readily prepared (Scheme 1).  The primary 
alcohol of geraniol (1) was protected with the pivaloate ester to prevent 
competition with the secondary alcohol of the diol (4) in opening the epoxide 
(3).  The geranyl pivaloate (2) was oxidized with mCPBA to form the epoxide 
(3), which was hydrolyzed with strong aqueous acid to make the diol (4). 
 With a generous supply of racemic epoxide (3) and diol (4) in hand, we 
began a series of experiments to identify a suitable Lewis acid catalyst for 
their complexation to form the ether-linked dimer.  We first tried BiCl3, a 
Lewis acid catalyst which had been reported to promote efficient epoxide 
















a Reagents and Conditions: (a) PivCl, py, CH2Cl2, 0 °C, 3 h, 88%; (b) mCPBA, 
CH2Cl2, 0 °C, 2 h, 65%; (c) H2SO4, THF, rt, 45 m, 62%. 
 
epoxide had been reported using BiCl3, when we tried the reaction between 
styrene oxide (5) and isopropanol, we observed only partial formation of the 
resulting -alkoxy alcohol (6).  Furthermore, the trial was conducted using 
isopropanol as both a reagent and the solvent simultaneously, a luxury we 
could not afford with the precious diol (4).  When this experiment was 
repeated without using a large excess of the alcohol (8 mol eq), no product (6) 
was observed, even when the reaction mixture was heated to reflux and the 
amount of catalyst increased five-fold.  To conclusively verify that these 
results apply to our system, racemic epoxide (3) and diol (4) were subjected to 
the BiCl3 catalyst and no product was observed.  Thus, BiCl3 is not a suitable 

























a Reagents and Conditions: (a) BiCl3 (0.1 mol eq), isopropanol, rt, 2 h, 39%; (b) 
BiCl3 (0.5 mol eq), isopropanol (8 mol eq), benzene, reflux, 4 h; (c) BiCl3 (0.25 
mol eq), hexafluoroisopropanol, rt, 48 h. 
 
 We next turned our attention towards the newly reported CuII(BF4)2 
Lewis acid catalyst.17  Based on a reported epoxide opening using only 4 mole 
equivalents of methanol to afford the opened epoxide product in 99% yield, it 
looked to be very promising for our purposes.  The first trial of CuII(BF4)2 
with our racemic system (Scheme 3) afforded the desired product, which was 
confirmed to be the sought-after dimer (7) by 1H and 13C NMR spectroscopy 























a Reagents and Conditions: (a) CuII(BF4)2 (0.1 mol eq), CH2Cl2, rt, 20 h, 9%; (b) 
CuII(BF4)2 (0.3 mol eq), CH2Cl2, reflux, 24 h, 28%. 
 
product (7) could be increased by raising the temperature of the reaction and 
increasing the mole equivalent of CuII(BF4)2 catalyst used.  Thus, we had 
identified CuII(BF4)2 to be a suitable Lewis acid catalyst for promoting the 





Having identified a reliable method for synthesizing the ether-linked 
dimer with the racemic model system, we concentrated our efforts on a 
stereocontrolled synthesis.  The protected geranyl pivaloate (2) already on 
hand was oxidized to the corresponding (S)-diol (8) and (R)-diol (9) using the 
Sharpless method of asymmetric dihydroxylation (Scheme 4).19  It is 
noteworthy that both in these oxidations as well as in the oxidation of 2 to 3, 
the reactions are cleanly regioselective towards the terminal alkene.  The 
other alkene is thought to avoid oxidation due to the proximity of the 
















rt = -22.4 (c 0.0125, MeOH) [  ]D
rt = +23.2 (c 0.0125, MeOH)  
 
a Reagents and Conditions: (a) AD-mix- , MeSO2NH2, 1:1 (v/v) H2O:t-BuOH, 
0 °C, overnight, 95%; (b) AD-mix-ß, MeSO2NH2, 1:1 (v/v) H2O:t-BuOH, 0 °C, 
overnight, 62%. 
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 The optical rotations of diols 8 and 9 were found to be opposite of each 
other and of approximately the same magnitude as the optical rotations of 
the corresponding diols of geranyl acetate,13 suggesting the possibility of 
optical purity.  However, optical rotation data can be unreliable, and we were 
interested in quantitatively determining the enantiomeric excesses of the 
desired diol isomers. 
 The first strategy for determining the enantiomeric excess was to 
transform the secondary alcohol of the diol into the corresponding Mosher 
ester and analyze the ratio of diastereomers thus formed with NMR 
spectroscopy.21  However, this method proved to be unsuccessful.  Due to the 
small reaction scales and losses during purification, 1H NMR could not detect 
the minor stereoisomers.  19F NMR seemed promising due to its greater 
sensitivity in this case, however the signal peaks were transient and thus 
could not be correlated to specific stereoisomers.  Furthermore, 19F NMR 
analysis of Mosher esters has been demonstrated to be unreliable.16 
 The next strategy was to allow the diols to complex to the chiral 
lanthanide NMR shift reagent Eu(hfc)3 and then analyze these formed 
complexes by 1H NMR.22  Diols 8 and 9 were combined in an NMR tube in 
mole ratios of 1:2 and 1:1 with 0.8 mole equivalents of Eu(hfc)3 and analyzed 
by 1H NMR.  Two sets of signals with integration ratios very similar to the 
known mole ratios of diols 8 and 9 were readily identified in each spectrum 
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recorded.  Then, diols 8 and 9 were individually analyzed by 1H NMR in the 
presence of 0.8 mole equivalents of Eu(hfc)3 and the integrations of the major 
and minor stereoisomer signals were used to determine the enantiomeric 
excess.  For both 8 and 9, the enantiomeric excess of the major stereoisomer 
was found to be greater than 96%. 
 Having established the high enantiomeric purity of the first 
stereospecific synthetic intermediates 8 and 9, we attempted to convert these 
diols to their corresponding epoxides.  This seemingly facile transformation 
presented a synthetic challenge which we had not anticipated.  All reactions 
we tried shared the common strategy of making the secondary alcohol a 
better leaving group and then promoting SN2 attack with the tertiary alcohol, 
thus displacing the derivatized secondary alcohol and forming the epoxide 
ring.  However, significant steric bulk around both alcohols prevented an 
efficient reaction. 
 Once the supply of racemic diol (4) was exhausted, stereopure diols 8 
and 9 were alternated in these epoxidation trials (Scheme 5).   Racemic diol 
(4) was converted into the secondary tosylate and treated with the mild base 
TEA.  No epoxide product was observed from this reaction despite letting it 
run overnight.  (S)-diol (8) was also converted to the corresponding tosylate; 
when treated with the strong base NaH, a small amount of epoxide (10) was 































a Reagents and Conditions: (a) TsCl, TEA, CH2Cl2, rt, overnight; (b) TsCl, 
NaH, benzene, rt, overnight, 22%; (c) MsCl, py, THF, 0 °C, overnight; (d) 
NaH, rt, 5 h, 26%. 
 
corresponding mesylate and NaH was introduced as a second step, the yield 
of epoxide (11) was observed to increase.  Even so, the largest yield obtained 
was only 26%, which did not provide enough material to allow making the 
stereospecific ether-linked dimers.  Time did not permit us to discover an 
efficient method of transforming the diol into the epoxide, though if greater 






 We have determined a suitable method for achieving the key dimer 
intermediate 7 and progressed along the stereocontrolled synthetic route 
toward GF-I-1.  Once optimal reaction conditions are worked out for the 
formation of epoxides 10 and 11, they can be easily opened by diols 8 and 9 
(Scheme 6, shown for the 6S,6'R diastereomer of GF-I-1), as has already been 
done with the racemic system.  The coupling of the two stereopure diols with 














































diastereomers of the ether-linked dimer.  Each of these four diastereomeric 
dimers can then be deprotected with mild base to return the primary 
alcohols, followed by Mitsunobu coupling23 to the psoralen heterocycle to form 
GF-I-1. 
 Comparisons of optical rotation data and 1H NMR spectroscopic data of 
the four diastereomers with those of the natural GF-I-1 should result in the 
unequivocal assignment of the absolute stereochemistry of natural GF-I-1.  
The four diastereomers can then be bioassayed on their inhibition of CYP3A4 





 General Methods.  All moisture and air sensitive reactions were 
performed in oven dried glassware equipped with rubber septa under a 
positive pressure of nitrogen or argon.  When necessary, solvents were 
distilled prior to use.  Reaction mixtures were magnetically stirred.  Thin 
layer chromatography was performed on Merck precoated silica gel 5534-3 
plates (0.2 mm).  Concentration in vacuo was generally performed using a 
Büchi rotary evaporator and a high vacuum oil pump.  Flash column 
chromatography was performed on Merck 70–230 mesh silica gel under a 
positive pressure of nitrogen.  Optical rotations were determined using a 
Perkin-Elmer 241 polarimeter.  Nuclear magnetic resonance spectra were 
recorded with Varian model Mercury 300 or UnityINOVA 400 instruments.  
1H NMR spectra were obtained with CDCl3 as solvent using TMS as an 
internal standard (0 ppm).  13C NMR spectra were recorded in ppm relative to 
the solvent signal: CDCl3 (77 ppm).  Electrospray mass spectra were recorded 
on a Micromass model LCT spectrometer and are reported in units of mass to 
charge (m/z). 
Geranyl pivaloate (2).  To a stirred solution of 1 (6.47 g, 42 mmol) and 
pyridine (6.4 mL, 84 mmol) in CH2Cl2 (40 mL) at 0 °C was added pivaloyl 
chloride (7.8 mL, 63 mmol).  The solution was stirred for 3 h at that 
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temperature.  The reaction was quenched with sat. NH4Cl (80 mL) and 
extracted with CH2Cl2 (40 mL).  The organic layer was washed with sat. 
NH4Cl (2 x 80 mL) and sat. CuSO4 successively.  The combined organic layers 
were dried with Na2SO3, filtered, and the solvent was removed in vacuo.  
Column chromatography (50:1 hexane:ethyl acetate) afforded 2 in 88% yield 
(8.77 g).  1H-NMR (400 MHz, CDCl3)  5.32 (tq, J = 7.0, 1.5 Hz, 1H), 5.08 (tt, J 
= 6.9, 1.5 Hz, 1H), 4.57 (d, J = 7.0 Hz, 2H), 2.06 (m, 4H), 1.68 (d, J = 7.5 Hz, 
6H), 1.60 (s, 3H), 1.20 (s, 9H). 
 Racemic 6,7-epoxygeranyl pivaloate (3).  To a stirred solution of 2   
(4.66 g, 19.6 mmol) in CH2Cl2 (117 mL) at 0 °C was added mCPBA (5.83 g).  
The solution was stirred for 2 h at that temperature.  The reaction mixture 
was filtered, washed with 10% aq. Na2SO3 (100 mL) and 10% aq. Na2CO3 (100 
mL), dried with MgSO4, and filtered.  The solvent was removed in vacuo and 
column chromatography (100:6 hexane:ethyl acetate) afforded 3 in 65% yield 
(3.24 g).  1H NMR (400 MHz, CDCl3)  5.37 (tq, J = 7.0, 1.1 Hz, 1H), 4.58 (d, J 
= 6.9 Hz, 2H), 2.70 (t, J = 6.2 Hz, 1H), 2.19 (m, 2H), 1.73 (s, 3H), 1.66 (m, 2H), 
1.31, (s, 3H), 1.27 (s, 3H), 1.19 (s, 9H); 13C NMR (100 MHz, CDCl3)  178.50, 
140.63, 119.36, 63.84, 61.17, 58.30, 38.70, 36.13, 27.17, 24.81, 22.61, 18.72, 
16.43, 14.07. 
 Racemic 6,7-dihydroxygeranyl pivaloate (4).  To a stirred solution of 3 
(2.5 g, 9.84 mmol) in THF (180 mL) was added 5M H2SO4 dropwise (8.4 mL).  
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The solution was stirred for 45 m at room temperature.  The reaction 
mixture was poured onto brine (200 mL) and extracted with diethyl ether (3 x 
100 mL).  The combined organic layers were dried with Na2SO4, filtered, and 
the solvent was removed in vacuo.  Column chromatography (15:1 hexane: 
ethyl acetate) afforded 4 in 62% yield (1.57 g).  1H NMR (400 MHz, CDCl3)  
5.38 (tq, J = 7.0, 1.1 Hz, 1H), 4.58 (d, J = 6.6 Hz, 2H), 3.33 (dd, J = 10.4, 1.8 
Hz, 1H), 2.48 (br, 1H), 2.32 (m, 1H), 2.14 (m, 1H), 1.72 (s, 3H), 1.61 (m, 1H), 
1.46 (m, 1H), 1.21 (s, 3H), 1.19 (s, 9H), 1.17 (s, 3H). 
 1-phenyl-1-isopropoxyethanol (6).  To a stirred solution of 5 (360 mg, 3 
mmol) in isopropanol (15 mL) at reflux was added BiCl3 (95 mg, 0.1 mol eq).  
The solution was stirred for 2 h at reflux.  The solvent was removed in vacuo 
and the crude reaction mixture was dissolved in diethyl ether (15 mL) and 
poured onto H2O (15 mL).  The organic phase was separated, and the aqueous 
phase was extracted with diethyl ether (2 x 15 mL).  The combined organic 
layers were dried with MgSO4, filtered, and the solvent was removed in 
vacuo.  Column chromatography (1:1 hexane:ethyl acetate) afforded 6 in 39% 
yield (209 mg).  1H NMR (400 MHz, CDCl3)  7.40 (m, 5H), 4.53 (dd, J = 8.0, 
4.7 Hz, 1H), 3.60 (m, 3H), 2.33 (br, 1H), 1.19 (d, J = 6.2 Hz, 3H), 1.13 (d, J = 
6.2 Hz, 3H); 13C NMR (100 MHz, CDCl3)  128.41, 127.89, 126.79, 79.92, 
69.54, 67.49, 23.45. 
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 Racemic dimer (7).  To a stirred solution of 3 (60 mg, 0.236 mmol) and 4 
(244 mg, .897 mmol) in CH2Cl2 (1 mL) was added CuII(BF4)2 catalyst (15 mg, 
.30 mol eq).  The solution was stirred for 24 h at reflux.  The reaction mixture 
was quenched with H2O (20 mL), and extracted with CH2Cl2 (3 x 20 mL).  The 
combined organic layers were washed with brine (60 mL), dried with Na2SO4, 
filtered, and the solvent was removed in vacuo.  Column chromatography 
(15:1 hexane:ethyl acetate) afforded 7 in 28% yield (40 mg).  1H NMR (400 
MHz, CDCl3)  5.38 (td, J = 6.9, 1.2 Hz, 2H), 4.58 (d, J = 6.9 Hz, 4H), 3.53 (tq, 
J = 11.2, 2.2 Hz, 2H), 2.34 (m, 2H), 2.14 (m, 2H), 2.07 (m, 2H), 1.72 (s, 6H), 
1.66 (s, 6H), 1.56 (m, 2H), 1.45 (m, 2H), 1.37 (s, 6H), 1.31 (s, 6H), 1.19 (s, 
18H); 13C NMR (100 MHz, CDCl3)  178.59, 141.17, 119.33, 98.74, 97.10, 
76.26, 76.04, 61.21, 38.72, 36.07, 29.14, 29.09, 27.18, 23.65, 23.40, 21.37, 
21.14, 16.45; ES MS found: m/z 531.4, calcd for [C30H54O7 + Na+ –  H2O]: m/z 
531. 
 (S)-6,7-dihydroxygeranyl pivaloate (8).  To a stirred solution of H2O (80 
mL) and t-BuOH (80 mL) at 0 °C were added the AD-mix-  very slowly   
(20.6 g), MeSO2NH2 (1.40 g), and 2 (3.97 mL, 14.7 mmol), successively.  The 
solution was stirred overnight at that temperature.  The reaction mixture 
was quenched with Na2SO3 (22.0 g).  The organic layers were extracted with 
ethyl acetate (3 x 80 mL), washed with 2M KOH (2 x 200 mL), dried with 
MgSO4, and filtered.  The solvent was removed in vacuo and column 
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chromatography (20:1 CH2Cl2:MeOH) afforded 8 in 95% yield (3.81 g).      
[ ]Drt -22.4 (c 0.0125 in MeOH); 1H NMR (400 MHz, CDCl3)  5.39 (tq, J = 6.7, 
1.1 Hz, 1H), 4.58 (dd, J = 7.0, 0.7 Hz, 2H), 3.35 (dd, J = 10.5, 1.8 Hz, 1H), 2.31 
(m, 2H), 2.13 (m, 2H), 1.72 (s, 3H), 1.66 (m, 3H), 1.46 (m, 1H), 1.21 (s, 3H), 
1.20 (s, 9H), 1.17 (s, 3H).  
 (R)-6,7-dihydroxygeranyl pivaloate (9).  To a stirred solution of H2O (80 
mL) and t-BuOH (80 mL) at 0 °C were added the AD-mix-ß very slowly (20.6 
g), MeSO2NH2 (1.40 g), and 2 (2.50 mL, 9.26 mmol), successively.  The 
solution was stirred overnight at that temperature.  The reaction mixture 
was quenched with Na2SO3 (22.0 g).  The organic layers were extracted with 
ethyl acetate (3 x 80 mL), washed with 2M KOH (2 x 200 mL), dried with 
MgSO4, and filtered.  The solvent was removed in vacuo and column 
chromatography (20:1 CH2Cl2:MeOH) afforded 9 in 62% yield (1.56 g).      
[ ]Drt +23.2 (c 0.0125 in MeOH); 1H NMR (400 MHz, CDCl3)  5.37 (tq, J = 
6.8, 1.1 Hz, 1H), 4.58 (d, J = 6.9 Hz, 2H), 3.34 (d, J = 10.4 Hz, 1H), 2.46 (br, 
1H), 2.32 (m, 1H), 2.21 (br, 1H), 2.12 (m, 1H), 1.72 (s, 3H), 1.61 (m, 1H), 1.46 
(m, 1H), 1.21 (s, 3H), 1.19 (s, 9H), 1.17 (s, 3H). 
(R)-6,7-epoxygeranyl pivaloate (10).  To a stirred solution of 8 (200 mg, 
0.736 mmol) and tosyl chloride (74 mg, 0.772 mmol) in benzene (16 mL) was 
added NaH slowly (58 mg).  The solution was stirred overnight at room 
temperature.  The reaction mixture was quenched with H2O (32 mL) and 
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extracted with ethyl acetate (16 mL).  The organic layer was washed with 
H2O (2 x 32 mL), dried with MgSO4, filtered, and the solvent was removed in 
vacuo.  Column chromatography (10:1 hexane:ethyl acetate) afforded 10 in 
22% yield (42 mg).  1H NMR (400 MHz, CDCl3)  5.37 (tq, J = 7.0, 1.5 Hz, 1H), 
4.58 (d, J = 6.9 Hz, 2H), 2.71 (t, J = 6.2 Hz, 1H), 2.17 (m, 2H), 1.73 (s, 3H), 
1.68 (m, 2H), 1.31 (s, 3H), 1.27 (s, 3H), 1.19 (s, 9H); 13C NMR (75 MHz, CDCl3) 
d 178.49, 140.61, 119.44, 119.18, 63.99, 63.68, 61.41, 61.14, 60.86, 60.31, 
58.31, 38.66, 36.09, 27.25, 27.01, 24.90, 24.67, 20.99, 20.95, 18.80, 18.56, 
16.49, 16.32, 14.24, 14.01. 
(S)-6,7-epoxygeranyl pivaloate (11).  To a stirred solution of 9 (200 mg, 
0.736 mmol) and pyridine (1 mL) in THF (5 mL) at 0 °C was added the mesyl 
chloride dropwise (91 µL).  The solution was stirred overnight at that 
temperature.  NaH (210 mg) and additional THF (5 mL) were added to the 
reaction mixture, and it was allowed to stir for an additional 5 h.  The 
reaction was quenched with H2O (15 mL).  The organic layer was extracted 
with ethyl acetate (15 mL) and washed with sat. CuSO4 (2 x 20 mL) and brine 
(20 mL).  The combined organic layers were dried with Na2SO4, filtered, and 
the solvent was removed in vacuo.  Column chromatography (10:1 hexane: 
ethyl acetate) afforded 11 in 26% yield (49 mg).  1H NMR (400 MHz, CDCl3)  
5.37 (tq, J = 6.9, 1.5 Hz, 1H), 4.58 (d, J = 6.8 Hz, 2H), 2.71 (t, J = 6.2 Hz, 1H), 
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